Orthosteric and allosteric action of the C5a receptor antagonists.

Article Details

Citation

Copy to clipboard

Liu H, Kim HR, Deepak RNVK, Wang L, Chung KY, Fan H, Wei Z, Zhang C

Orthosteric and allosteric action of the C5a receptor antagonists.

Nat Struct Mol Biol. 2018 Jun;25(6):472-481. doi: 10.1038/s41594-018-0067-z. Epub 2018 Jun 4.

PubMed ID

29867214 [ View in PubMed

]

Abstract

The C5a receptor (C5aR) is a G-protein-coupled receptor (GPCR) that can induce strong inflammatory response to the anaphylatoxin C5a. Targeting C5aR has emerged as a novel anti-inflammatory therapeutic method. However, developing potent C5aR antagonists as drugs has proven difficult. Here, we report two crystal structures of human C5aR in ternary complexes with the peptide antagonist PMX53 and a non-peptide antagonist, either avacopan or NDT9513727. The structures, together with other biophysical, computational docking and cell-based signaling data, reveal the orthosteric action of PMX53 and its effect of stabilizing the C5aR structure, as well as the allosteric action of chemically diverse non-peptide C5aR antagonists with different binding poses. Structural comparison analysis suggests the presence of similar allosteric sites in other GPCRs. We also discuss critical structural features of C5aR in activation, including a novel conformation of helix 8. On the basis of our results, we suggest novel strategies for developing C5aR-targeting drugs.

DrugBank Data that Cites this Article

Drugs

Avacopan

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Avacopan	C5a anaphylatoxin chemotactic receptor 1	Protein	Humans	Yes	Antagonist	Details